Study guide
6.1 Dose-Response Relationships and Points of Departure
CIH Certified Industrial Hygienist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The CIH Exam and How to Use This Guide
1.1 CIH Exam Format, Scoring, and Test-Day Logistics 1.2 Eligibility, Application Windows, Fees, and Certification Maintenance 1.3 The BGC Blueprint, Subject Areas, and a Calculation-First Study Plan
2 Chapter 2: Basic Science & Calculations
2.1 Gas Laws and Vapor Calculations 2.2 Unit Conversions: ppm, mg/m³, and Standard Temperature/Pressure 2.3 Fluid Mechanics and Airflow Fundamentals
3 Chapter 3: Air Sampling & Instrumentation
3.1 Active and Passive Air Sampling Strategies 3.2 Particulate and Aerosol Sampling 3.3 Direct-Reading Instruments and Calibration
4 Chapter 4: Analytical Chemistry & Lab Methods
4.1 Gas Chromatography and Mass Spectrometry 4.2 High-Performance Liquid Chromatography and Ion Chromatography 4.3 Spectroscopy and Elemental Analysis 4.4 Gravimetric, Microscopy, and Wet Chemical Methods 4.5 Laboratory Quality Assurance, Chain of Custody, and Desorption Efficiency
5 Chapter 5: Biostatistics & Epidemiology
5.1 Lognormal Distributions and Exposure Data Statistics 5.2 Upper Confidence Limits (UCL95) and Compliance Decision Rules 5.3 Epidemiological Study Designs and Measures of Association 5.4 Sampling Strategy: Sample Size, Power, and Worker Selection
6 Chapter 6: Toxicology & Biological Monitoring
6.1 Dose-Response Relationships and Points of Departure 6.2 Toxicokinetics: Absorption, Distribution, Metabolism, and Elimination 6.3 Aerosol Deposition, Clearance, and Respiratory Tract Dosimetry 6.4 Hepatic, Renal, Neurologic, and Hematologic Target Organ Toxicity 6.5 Pulmonary Toxicology, Carcinogenicity, and Reproductive Hazards 6.6 OEL Frameworks, Classifications, and Excursion Limits 6.7 Chemical Mixtures and Extended Work-Shift OEL Adjustments 6.8 Biological Exposure Indices (BEIs) and Biomonitoring
7 Chapter 7: Biohazards & Indoor Environmental Quality
7.1 Mold, Fungi, and Microbial Contaminants 7.2 Infectious Agents, Bloodborne Pathogens, and Biosafety Levels 7.3 Indoor Environmental Quality (IEQ) Investigations 7.4 Sanitation, Potable Water, and Personal Hygiene Programs
8 Chapter 8: Community Exposure & Environmental Health
8.1 Clean Air Act Framework, NAAQS, and New Source Review 8.2 Hazardous Air Pollutants, CEMS, and EPA Reference Methods 8.3 Atmospheric Stability, Lapse Rates, and Plume Morphology 8.4 Gaussian Plume Modeling, Plume Rise, and Environmental Fate 8.5 HAZWOPER Scope, Mandates, and Training Tiers 8.6 Protection Levels, Site Zoning, Incident Command, and Decontamination 8.7 Water Pollution, Hazardous Waste, and Community Right-to-Know
9 Chapter 9: Health Risk Analysis & Hazard Communication
9.1 GHS Hazard Classification: Health and Physical Hazard Criteria 9.2 GHS Labels, Safety Data Sheets, and Trade Secret Rules 9.3 The AIHA Exposure Assessment Strategy and Similar Exposure Groups 9.4 Qualitative Exposure Profiling and the AIHA Risk Matrix 9.5 Quantitative Health Risk Characterization: HQ, HI, and ELCR 9.6 NIOSH Occupational Exposure Banding 9.7 Risk Communication and Reporting to Affected Parties
10 Chapter 10: Industrial Ventilation Principles & LEV Design
10.1 Elimination, Substitution, Isolation, Containment, and Process Change 10.2 LEV Hood Taxonomy and Capture Velocity Selection 10.3 Hood Airflow Equations, Entry Losses, and Hood Static Pressure 10.4 Particulate Transport Aerodynamics and Duct Sizing 10.5 Duct Friction, Fitting Losses, and System Balancing 10.6 Fan Categories and Pressure Dynamics Across the Fan 10.7 System Curves, the Fan Laws, and Density Corrections
11 Chapter 11: General Ventilation, Air Cleaning & Diagnostics
11.1 Dilution Ventilation Principles and Steady-State Modeling 11.2 Transient Purging and Air Distribution Geometry 11.3 Particulate Air Cleaning: Cyclones, Baghouses, Scrubbers, and ESPs 11.4 Gaseous Emission Control and Air Cleaner Selection 11.5 Ventilation System Troubleshooting and Testing
12 Chapter 12: Noise Measurement & Hearing Conservation
12.1 Acoustic Physics and Decibel Mathematics 12.2 Sound Propagation, Octave Bands, and Frequency Weighting 12.3 Noise Dose Metrics and OSHA versus ACGIH Criteria 12.4 Exchange Rates, Extended Shifts, and Dosimetry Field Protocols 12.5 Engineering Noise Controls and Hearing Protector Attenuation 12.6 Hearing Conservation Programs and Standard Threshold Shifts 12.7 Hand-Arm and Whole-Body Vibration
13 Chapter 13: Thermal Stress Assessment & Control
13.1 Wet Bulb Globe Temperature (WBGT) and Heat Stress Indices 13.2 Heat-Related Disorders, Acclimatization, and Work/Rest Regimens 13.3 Cold Stress Evaluation and Wind Chill
14 Chapter 14: Ionizing Radiation Protection
14.1 Ionizing Radiation Physics and Radioactive Decay Kinetics 14.2 Radiation Units, Radiobiology, and Health Effects 14.3 ALARA, Stay-Time, and the Inverse Square Law 14.4 Shielding Physics, Material Selection, and Gamma Constants 14.5 Radiation Detection Instruments and Spectrometry 14.6 Personnel Dosimetry, Dose Limits, and Contamination Surveys
15 Chapter 15: Non-Ionizing Radiation & Laser Safety
15.1 The Non-Ionizing Spectrum and Static/ELF Field Exposures 15.2 Radiofrequency and Microwave Exposure: SAR, Standards, and Surveys 15.3 Ultraviolet, Visible, and Infrared Radiation Hazards 15.4 Laser Safety Classifications and Optical Density Calculations 15.5 Illumination, Lighting Design, and Visual Performance
16 Chapter 16: Non-Engineering Controls & Personal Protective Equipment
16.1 Respiratory Protection Programs and Assigned Protection Factors 16.2 Maximum Use Concentration, Oxygen Deficiency, and Breathing Air 16.3 Particulate Filters, Sorbent Cartridges, and Change Schedules 16.4 Respirator Fit Testing Protocols 16.5 Chemical Protective Clothing and Dermal Exposure Control
17 Chapter 17: Ergonomics & Workstation Design
17.1 Soft-Tissue Biomechanics and WMSD Pathophysiology 17.2 Ergonomic Risk Factors and Their Interaction Effects 17.3 The Revised NIOSH Lifting Equation 17.4 RULA, REBA, the Strain Index, and the ACGIH HAL TLV 17.5 Anthropometry and Workstation Geometry 17.6 VDT Workstations, Hand Tool Design, and Administrative Ergonomics
18 Chapter 18: Work Environments & Industrial Processes
18.1 Welding Fume Emissions, Metal Fume Fever, and Cr(VI)/Manganese Toxicology 18.2 Foundry Operations and Hot Work Fire Prevention 18.3 Vapor Degreasing, Pickling, Electroplating, and Cyanide Baths 18.4 Spray Coatings, Isocyanates, and Semiconductor Manufacturing 18.5 Confined Spaces and High-Hazard Industrial Operations 18.6 Asbestos, Lead, and Silica: Regulated Substance Programs 18.7 Abrasive Blasting and Surface Preparation
19 Chapter 19: IH Program Management & Professional Ethics
19.1 The BGC Code of Ethics: Canons and Enforcement 19.2 Professional Liability, Standard of Care, and Expert Testimony 19.3 Occupational Health & Safety Management Systems (ISO 45001, ANSI Z10) 19.4 Exposure Records Access and Medical Surveillance 19.5 OSHA Injury and Illness Recordkeeping and Enforcement
6.1 Dose-Response Relationships and Points of Departure
Key Takeaways Explain This Topic AI
The dose-response curve is the organising principle of toxicology: threshold (non-carcinogenic) effects assume a NOAEL below which no adverse response occurs, while genotoxic carcinogens are modelled with no threshold.
The NOAEL, LOAEL, and benchmark dose lower confidence limit (BMDL) are the three points of departure from which occupational and environmental limits are derived by applying uncertainty factors.
LD50 and LC50 quantify acute lethality and are the basis of GHS acute toxicity categories; they say nothing about chronic or sub-lethal effects.
Potency (position of the curve on the dose axis) and efficacy (maximum attainable response) are independent properties — a more potent agent is not necessarily more dangerous at workplace concentrations.
Last updated: August 2026
Dose-Response Relationships and Points of Departure
Toxicology is the qualitative and quantitative study of the adverse effects of chemical, biological, and physical agents on living organisms. In industrial hygiene, toxicology provides the scientific bedrock for recognizing chemical hazards, establishing health-protective exposure standards, interpreting biological monitoring data, and designing effective risk management programs. This section reviews fundamental dose-response concepts, quantitative hazard metrics, and the mathematical framework of toxicokinetics—Absorption, Distribution, Metabolism, and Excretion ( ADME ).
1. Foundational Toxicology & Dose-Response Principles
The fundamental axiom of toxicology, first formulated by Paracelsus in the 16th century ( "Sola dosis facit venenum" — "Only the dose makes the poison"), states that all substances are toxic at a sufficient dose. In occupational health, the critical distinction lies in the relationship between the internal dose received by a worker and the magnitude or frequency of the resulting biological effect .
Graded vs. Quantal Dose-Response Relationships
Graded (Continuous) Dose-Response:
Describes the response of an individual organism as the dose increases.
The severity of the effect increases continuously with dose (e.g., degree of cholinesterase enzyme inhibition, blood carboxyhemoglobin percentage, or reduction in forced expiratory volume in 1 second, FEV1).
Typically plotted as effect magnitude on the y-axis versus log-dose on the x-axis, producing a characteristic hyperbolic or sigmoidal curve.
Quantal (All-or-None) Dose-Response:
Describes the response of a population of individuals.
The response is binary—either an individual exhibits a specific defined effect or does not (e.g., mortality, development of an occupational tumor, sensory irritation threshold).
When cumulative percentage response is plotted against log-dose, a symmetrical sigmoidal (S-shaped) curve emerges. When transformed using Probit units (standard normal deviations + 5 to avoid negative numbers), the sigmoidal curve linearizes, enabling precise statistical regression for median response doses. +-------------------------------------------------------------+
- | DOSE-RESPONSE CURVE ARCHETYPES |
- +-------------------------------------------------------------+
- | % Response |
- | 100 | /--- Non-Carcinogen / Threshold |
- | | / |
- | 50 | / /-- Genotoxic Carcinogen (LNT) |
- | | / / |
- | 0 +-----------------/---/------------------------> |
- | 0 Threshold Dose (Log Scale) |
- +-------------------------------------------------------------+
- Threshold vs. Non-Threshold (LNT) Concepts
Threshold Toxicants (Non-Carcinogens & Non-Genotoxic Endpoints):
Biological premise: Organisms possess homeostatic defense mechanisms, reserve cellular capacity, DNA repair enzymes, and metabolic detoxification pathways that neutralize toxicants at low doses.
An adverse biological response occurs only after these physiological defense reserves are overwhelmed.
Below the threshold dose, the probability of the adverse effect is virtually zero. Occupational Exposure Limits (OELs, TLVs, PELs) for systemic toxicants and organ toxins are derived based on threshold concepts.
Non-Threshold / Linear No-Threshold (LNT) Toxicants (Genotoxic Carcinogens & Ionizing Radiation):
Biological premise: A single molecule of an electrophilic chemical mutagen or a single ionizing track can interact directly with nuclear DNA, inducing an unrepaired somatic mutation in a proto-oncogene or tumor suppressor gene that can initiate neoplastic clonal expansion.
Theoretically, no safe dose exists; any exposure above zero carries a finite, non-zero probability of inducing cancer.
Regulatory bodies (OSHA, EPA, NIOSH) evaluate carcinogens using linearized multistage models, expressing risks as excess cancer incidence per unit exposure (e.g., 10⁻⁴ or 10⁻⁶ lifetime risk).
2. Points of Departure and Quantitative Hazard Metrics
In toxicological risk assessment, experimental animal and human epidemiological data are evaluated to identify a Point of Departure (POD) —the toxicological dose benchmark used to extrapolate safe occupational exposure boundaries. +-------------------------------------------------------------+
- | POINTS OF DEPARTURE ON A CURVE |
- +-------------------------------------------------------------+
- | Response (%) |
- | ^ |
- | | * High Adverse Effect|
- | | * |
- | | * LOAEL (First significant effect) |
- | 10 |-------------* BMDL10 (95% Lower confidence on BMD) |
- | | * NOAEL (No statistically significant effect)|
- | 0 +----------+-----+-----------------------------------> |
- | NOAEL LOAEL Dose (mg/kg/day) |
- +-------------------------------------------------------------+
- Definitions of Core Toxicological Points of Departure
Metric Full Term Definition & Application
NOAEL No Observed Adverse Effect Level The highest experimental exposure dose or concentration at which there is no statistically or biologically significant increase in frequency or severity of adverse effects compared to controls.
LOAEL Lowest Observed Adverse Effect Level The lowest experimental exposure dose or concentration at which a statistically or biologically significant increase in adverse effects is observed.
BMD / BMDL Benchmark Dose / BMD Lower Confidence Limit The statistical lower bound (typically 95% lower confidence limit, BMDL10) of the dose that results in a specified benchmark response rate (e.g., 10% excess risk over control). Overcomes NOAEL sample-size dependency.
Uncertainty Factors (UFs) in Setting Exposure Limits
When deriving acceptable human exposure metrics—such as an EPA Reference Dose (RfD), an ACGIH TLV, or an occupational target limit—from an animal or subchronic study, safety/uncertainty factors are applied multiplicatively: R f D = POD (NOAEL or BMDL 10 ) ∏ UF = NOAEL U F A × U F H × U F S × U F L × U F D RfD = \frac{\text{POD (NOAEL or } \text{BMDL}_{10}\text{)}}{\prod \text{UF}} = \frac{\text{NOAEL}}{UF_A \times UF_H \times UF_S \times UF_L \times UF_D} R f D = ∏ UF POD (NOAEL or BMDL 10 ) = U F A × U F H × U F S × U F L × U F D NOAEL
UFA (Interspecies Extrapolation, 10×): Accounts for pharmacokinetic and pharmacodynamic differences between experimental animals and humans.
UFH (Intraspecies / Human Variability, 10×): Accounts for genetic polymorphisms, age, pre-existing disease, and nutritional variance within human populations.
UFS (Subchronic to Chronic Duration, 10×): Applied when only a 90-day subchronic study is available to predict lifetime chronic occupational exposure.
UFL (LOAEL to NOAEL Extrapolation, 10×): Applied when a true NOAEL was not established in the study and extrapolation starts from a LOAEL.
UFD (Database Incompleteness, 3× to 10×): Applied when essential reproductive, developmental, or chronic toxicity data are missing.
Acute Lethality Indices: LD50, LC50, and Haber's Rule
LD50 (Median Lethal Dose): The statistically calculated dose of a chemical required to kill 50% of an animal test population under specified experimental conditions, expressed in milligrams of toxicant per kilogram of body weight (extmg/kg) .
LC50 (Median Lethal Concentration): The statistically calculated concentration of a vapor, gas, or airborne particulate in air required to kill 50% of a test population over a specified exposure duration (e.g., 4-hour LC50), expressed in ppm or mg/m³ .
Haber's Rule of Inhalation Toxicity
For acute, cumulative chemical exposures, Haber's Rule states that the product of exposure concentration (C) and duration (t) produces a constant biological effect (k): C × t = k C \times t = k C × t = k
Limitation: Haber's rule fails for rapidly detoxified substances (where detoxification rate prevents accumulation at low concentrations over long durations) and sensory irritants (where effect depends on instantaneous peak concentration rather than integrated time-dose product).
Therapeutic Index vs. Margin of Safety
In classical pharmacology and industrial toxicology, relative safety is evaluated by comparing the lethal dose curve with the effective/toxic threshold curve: Therapeutic Index (TI) = LD 50 ED 50 \text{Therapeutic Index (TI)} = \frac{\text{LD}_{50}}{\text{ED}_{50}} Therapeutic Index (TI) = ED 50 LD 50 Margin of Safety (MOS) = LD 01 ED 99 \mathbf{\text{Margin of Safety (MOS)} = \frac{\text{LD}_{01}}{\text{ED}_{99}}} Margin of Safety (MOS) = ED 99 LD 01
Exam Key Concept: The Therapeutic Index (TI) can be misleading because it only compares median points (extLD50 and extED50) and ignores curve slopes. If two chemicals have identical median ratios but different dose-response slopes, the one with a flatter lethal slope may produce lethal fatalities at doses within the "effective" range. The Margin of Safety (MOS) compares the 1% lethal threshold (LD01) to the 99% effective threshold (ED99), providing a rigorous assessment of overlapping toxicity.